NEW ORLEANS, April 3, 2011 /PRNewswire/ -- A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's (NYSE: ABT) market-leading XIENCE V® Everolimus Eluting Coronary Stent System. As part of the analysis of all four trials, two-year results on the safety and efficacy of XIENCE V compared to TAXUS® Liberte® and TAXUS® Express2™ Paclitaxel-Eluting Coronary Stent Systems (TAXUS) were presented at the American College of Cardiology's (ACC) 60th Annual Scientific Session and i2 Summit 2011 in New Orleans.
In a presentation given by Dean J. Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center in Cincinnati, Ohio, predictors of artery re-blockage, cardiac death or heart attack were evaluated out to two years in nearly 7,000 patients from the SPIRIT II, III, IV and COMPARE clinical trials. The data demonstrated that use of XIENCE V resulted in significantly lower clinical event rates following a stent procedure. In the pooled analysis, XIENCE V demonstrated a 36 percent reduction in the risk of major adverse cardiac events (MACE) compared to TAXUS (7.3 percent for XIENCE V versus 11.1 percent for TAXUS, p-value<0.001). MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or retreatment of a lesion (ischemia-driven target lesion revascularization, or ID-TLR).
"XIENCE V consistently demonstrated low adverse cardiac event rates in trial after trial," said Dr. Kereiakes. "The SPIRIT II, III, IV, and COMPARE pooled analysis suggests that XIENCE V reduced the occurrence of adverse events compared to patients treated with the TAXUS stent. The low event rates demonstrated by XIENCE V in these trials are esp